Drugs / HEV vaccine
HEV vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02584543 | Oct 2015 → Aug 2016 | hepatitis B virus infection, hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02584543 ↗ |
| Known as | Hepatitis E vaccine | “The concomitant group (n =300) received Hepatitis B vaccine concomitantly with Hepatitis E vaccine at day 1 and months 1 and 6;” NCT02584543 ↗ |
| Known as | Recombinant Hepatitis E Vaccine (Escherichia Coli) | “A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)” NCT02584543 ↗ |
| Modality | Vaccine | “Recombinant Hepatitis E Vaccine (Escherichia Coli)” NCT02584543 ↗ |